A Composite Assay for HER2-positive Early-stage Breast Cancer Management — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Composite Assay for HER2-positive Early-stage Breast Cancer Management — Stella

Recruiting

Back to Breast Cancer Early Stage Breast Cancer (Stage 1-3) trials

Trial locations(2 sites)

Italy

Ospedale Di Summa-Perrino, Brindisi

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples

Key details

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Collaborators

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Ospedale Di Summa-Perrino

Enrollment target

~180 participants

Started

November 2024

Primary completion

August 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated January 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov